Financials
Financial year 2025
SAB Pharma from Péruwelz, company number BE0687692485, closed financial year 2025 with a result of € 19,532 after tax. For that financial year SAB Pharma recorded a gross margin of € 38,513 and equity of € 29,522. Compared with financial year 2024, the result moved from € 10,102 to € 19,532. Profitable, and profit is growing. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 26, 2026.
€ 29,522
▼ 2% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 19,532
▲ 93% vs 2024
Profit after tax over the fiscal year.
€ 27,493
▲ 34% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 20,000 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 20,052
▼ 12% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 23,204
▼ 2% vs 2024
€ 12,641 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 2,583
▼ 34% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 11,572
▲ 112% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 101,341 | € 13,195 | € 27,063 | € 38,513 | ▲ 42% |
| Profit after taxes | € 74,478 | € 4,279 | € 10,102 | € 19,532 | ▲ 93% |
| Equity | € 99,789 | € 104,068 | € 29,990 | € 29,522 | ▼ 2% |
| Total debts | € 31,369 | € 43,655 | € 117,262 | € 76,613 | ▼ 35% |
| Cash | € 84,108 | € 9,838 | € 20,530 | € 27,493 | ▲ 34% |
| Retained profit | € 79,329 | € 83,608 | € 9,530 | € 9,062 | ▼ 5% |
| Dividend | € 0 | € 0 | € 84,181 | € 20,000 | ▼ 76% |
| Bank debt | € 17,281 | € 38,254 | € 23,736 | € 23,204 | ▼ 2% |
| Balance sheet total | € 131,158 | € 147,723 | € 147,252 | € 106,135 | ▼ 28% |
Key figures of SAB Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to SAB Pharma?
What happened at SAB Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 19,532 (▲ 93% vs 2024). filed late Source: NBB ↗
- New establishment in Péruwelz. KBO
- Start of the company according to the CBE. KBO
In short
From € 74,478 profit in 2022 to € 19,532 profit in 2025.
Paid € 26,946 in corporate taxes since 2022.
Best year ever: 2022, with € 74,478 profit.
Paid out € 104,181 in dividends to the owners in total.
Management
Behind SAB Pharma is AKIM BOUZIDI. AKIM BOUZIDI is also behind PHARMACIE ANSELME, PHARMACIE DE LA VERTE FEUILLE, BNA Santé and POLYCLINIQUE BNA SANTE.
Directors
According to the 2025 annual accounts
AKIM BOUZIDI
Director
Also active at: PHARMACIE ANSELME, PHARMACIE DE LA VERTE FEUILLE, BNA Santé, POLYCLINIQUE BNA SANTE
Establishments
Establishment units
Physical locations of this company
Rue de Gourgues(WIE) 21
7608 Péruwelz
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0687.692.485
- VAT number
- BE 0687.692.485
- Registered office
- Rue de Gourgues(WIE) 21, 7608 Péruwelz
- Names & denominations
- SAB Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 9 January 2018
- Peppol
- Active · Active since 12 Dec 2025
- Activities · NACE
Detailhandel in farmaceutische producten